Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Prostatic Neoplasms, Castration-Resistant × zimberelimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Triple Negative Breast Neoplasms 1 Solid Tumor 1 Prostatic Neoplasms, Castration-Resistant 1 Pancreatic Neoplasms 1 Colorectal Neoplasms 1 Breast Neoplasms 1

Interventions

enzalutamide 5 Docetaxel 3 zimberelimab 1 sacituzumab govitecan 1 quemliclustat 1 olaparib 1 gedatolisib 1 fludrocortisone acetate 1 darolutamide 1 cabazitaxel 1 abiraterone 1 Prednisone 1 Dexamethasone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Arcus Biosciences, Inc.

Phase 1/2 Completed

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡